David Einhorn speaking in New York City on April 3, 2024.
Adam Jeffery | CNBC
Hedge fund investor David Einhorn’s cautious stance all year made his performance suffer as he navigated what he believes is the priciest stock market of his career at Greenlight Capital.
Einhorn’s hedge fund returned just 9% in 2024 through the end of the third quarter, net of fees and expenses. That compares with the S&P 500′s more than 20% gain during the same period.
The high-profile investor said he’s neither calling the market a bubble nor being outright bearish, but sky-high prices caused him to be conservatively positioned.
“The market isn’t just making all-time highs. It is, by many measures, the most expensive stock market that we have seen since the founding of Greenlight,” Einhorn said in the latest investor letter last month. Einhorn founded Greenlight in 1996.
Einhorn is speaking at CNBC’s Delivering Alpha Investor Summit on Wednesday in New York City. It will be the first chance for investors to hear from Einhorn postelection and whether his views on equity valuations and inflation have changed with the Trump and Republican policies on the way.
After a buyers’ strike at the end of 2023, Einhorn came back in the market hunting opportunities, acquiring medium-sized positions in names like software firm Alight and drugmaker Viatris. Investors will be interested to hear if he’s still finding any values.
These new stock picks didn’t necessarily create a ton of alpha, however. Greenlight was hurt this year by its low net exposure to the market and a lack of investments in the red-hot Magnificent 7 names.
“We are likely to continue to underperform a rising market, as we have all year, but we don’t wish to position ourselves to lose money should the market continue to rise,” he said in the letter. “We think Paul Tudor Jones is right when he says that managing the last third of a great bull or bear market move is often the toughest.”
S&P 500, 5 years
Meanwhile, he spent most of this year calling for a reacceleration in inflation, making gold a very large position in his portfolio. This bet has fared relatively well even as inflation has moderated with spot gold hitting a record high in late October, up 27% this year.
Einhorn, a 55-year-old Cornell grad, founded Greenlight Capital nearly three decades ago and went on to produce a whopping 26% annualized return for the next decade, far outpacing the broader market and many peers. He then thrived during the financial crisis, predicting the fall of Lehman Brothers. His stellar track record made him one of the most followed hedge fund managers on Wall Street. In recent years, he’s found some success purchasing value stocks that have buyback strategies in place.
Check out the companies making headlines in premarket trading. Novo Nordisk — The stock jumped about 5%, rebounding from the nearly 18% losses seen in the previous session. On Friday, the Danish pharmaceutical giant’s experimental weight loss drug, CagriSema, reported late-stage trial results that missed expectations . Honda – U.S.-listed shares surged 15% after the company officially began merger talks with fellow Japanese automaker Nissan. The automakers plan to conclude discussions in June 2025. Xerox — The document services provider added nearly 7% after announcing its acquisition of printer maker Lexmark. The deal is worth $1.5 billion. Occidental Petroleum , Sirius XM , VeriSign — The stocks continued to rise in Monday’s premarket after Warren Buffett disclosed last week that his Berkshire Hathaway conglomerate added to its stake in each name. Occidental and Sirius XM each climbed more than 2%, while VeriSign advanced 1.8%. Tesla — The electric vehicle maker bounced 3% before the bell, regaining some ground after last week’s decline. Tesla slid 3.5% last week, which marked its worst weekly performance since before the U.S. presidential election. Despegar.com — Shares soared 32% after Prosus entered into a definitive agreement to buy the Argentina-based online travel platform for $19.50 per share. Prosus will pay $1.7 billion as part of the deal, which is expected to close in the second quarter of 2025. Traws Pharma — Shares of the clinical-stage virology company skyrocketed more than 76% after it announced progress in the development of its treatment for H5N1 bird flu. The company said tivoxavir marboxil showed safety and tolerability in the phase 1 trial, and it will begin a phase 2 study early next year. The news comes as the threat of bird flu is expected to rise. Immunocore — The biotech stock rose more than 5% on word that the first patient has been dosed with its experimental immunotherapy treatment, IMC-0115C. — CNBC’s Sean Conlon and Christina Cheddar Berk contributed reporting
Investors may want to consider adding exposure to the world’s second-largest emerging market.
According to EMQQ Global founder Kevin Carter, India’s technology sector is extremely attractive right now.
“It’s the tip of the spear of growth [in e-commerce] … not just in emerging markets, but on the planet,” Carter told CNBC’s “ETF Edge” this week.
His firm is behind the INQQ The India Internet ETF, which was launched in 2022. The India Internet ETF is up almost 21% so far this year, as of Friday’s close.
‘DoorDash of India’
One of Carter’s top plays is Zomato, which he calls “the DoorDash of India.” Zomato stock is up 128% this year.
“One of the reasons Zomato has done so well this year is because the quick commerce business blanket has exceeded expectations,” Carter said. “It now looks like it’s going to be the biggest business at Zomato.”
Carter noted his bullishness comes from a population that is just starting to go online.
“They’re getting their first-ever computer today basically,” he said, “You’re giving billions of people super computers in their pocket internet access.”